|
Market Closed -
Euronext Paris
19:55:00 18/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.8240 EUR | -3.74% |
|
0.00% | +18.73% |
| 07-22 | Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications | CI |
| 06-29 | Valbiotis Raises EUR10 Million for Commercial Development, Working Capital | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 23.46M | - | ||||
| 73.25B | |||||
| 61.95B | |||||
| 28.02B | - | ||||
| 24.15B | |||||
| 23.01B | - |
- Stock Market
- Stocks
- ALVAL Stock
- Charts Valbiotis
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
